{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T10:47:05Z","timestamp":1776422825014,"version":"3.51.2"},"reference-count":51,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["semradonc.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Radiation Oncology"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.semradonc.2015.08.002","type":"journal-article","created":{"date-parts":[[2015,8,29]],"date-time":"2015-08-29T10:39:27Z","timestamp":1440844767000},"page":"9-16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Molecular Phenotype, Multigene Assays, and the Locoregional Management of Breast Cancer"],"prefix":"10.1016","volume":"26","author":[{"given":"Lior Z.","family":"Braunstein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alphonse G.","family":"Taghian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.semradonc.2015.08.002_bib1","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJM199811263392207","article-title":"Tamoxifen in the treatment of breast cancer","volume":"339","author":"Wood","year":"1998","journal-title":"N Engl J Med"},{"issue":"29","key":"10.1016\/j.semradonc.2015.08.002_bib2","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.1200\/JCO.2011.36.1105","article-title":"Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy","volume":"29","author":"Arvold","year":"2011","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.semradonc.2015.08.002_bib3","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1200\/JCO.2005.05.145","article-title":"Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling","volume":"23","author":"Jansen","year":"2005","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.semradonc.2015.08.002_bib4","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1056\/NEJMc0801440","article-title":"HER2 status and benefit from adjuvant trastuzumab in breast cancer","volume":"358","author":"Paik","year":"2008","journal-title":"N Engl J Med"},{"issue":"7418","key":"10.1016\/j.semradonc.2015.08.002_bib5","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","author":"Cancer Genome Atlas Network","year":"2012","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.semradonc.2015.08.002_bib6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1158\/2159-8290.CD-12-0462","article-title":"The genomic landscape of breast cancer as a therapeutic roadmap","volume":"3","author":"Ellis","year":"2013","journal-title":"Cancer Discov"},{"issue":"6797","key":"10.1016\/j.semradonc.2015.08.002_bib7","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"Perou","year":"2000","journal-title":"Nature"},{"issue":"14","key":"10.1016\/j.semradonc.2015.08.002_bib8","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1200\/JCO.2007.14.4287","article-title":"Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy","volume":"26","author":"Nguyen","year":"2008","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.semradonc.2015.08.002_bib9","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1245\/s10434-009-0606-2","article-title":"Presenting features of breast cancer differ by molecular subtype","volume":"16","author":"Wiechmann","year":"2009","journal-title":"Ann Surg Oncol"},{"issue":"27","key":"10.1016\/j.semradonc.2015.08.002_bib10","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1056\/NEJMoa041588","article-title":"A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer","volume":"351","author":"Paik","year":"2004","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.semradonc.2015.08.002_bib11","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1200\/JCO.2008.18.1370","article-title":"Supervised risk predictor of breast cancer based on intrinsic subtypes","volume":"27","author":"Parker","year":"2009","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.semradonc.2015.08.002_bib12","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1056\/NEJMoa021967","article-title":"A gene-expression signature as a predictor of survival in breast cancer","volume":"347","author":"Van De Vijver","year":"2002","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.semradonc.2015.08.002_bib13","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0002-9440(10)63093-3","article-title":"Measurement of gene expression in archival paraffin-embedded tissues: Development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay","volume":"164","author":"Cronin","year":"2004","journal-title":"Am J Pathol"},{"issue":"24","key":"10.1016\/j.semradonc.2015.08.002_bib14","doi-asserted-by":"crossref","first-page":"8623","DOI":"10.1158\/1078-0432.CCR-05-0735","article-title":"Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes","volume":"11","author":"Cobleigh","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.semradonc.2015.08.002_bib15","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1470-2045(09)70314-6","article-title":"Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: A retrospective analysis of a randomised trial","volume":"11","author":"Albain","year":"2010","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.semradonc.2015.08.002_bib16","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1200\/JCO.2009.24.4798","article-title":"Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: A TransATAC study","volume":"28","author":"Dowsett","year":"2010","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.semradonc.2015.08.002_bib17","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.amjsurg.2008.06.021","article-title":"Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?","volume":"196","author":"Asad","year":"2008","journal-title":"Am J Surg"},{"issue":"14","key":"10.1016\/j.semradonc.2015.08.002_bib18","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1093\/jnci\/djs261","article-title":"Clinical validity\/utility, change in practice patterns, and economic implications of risk stratifiers to predict outcomes for early-stage breast cancer: A systematic review","volume":"104","author":"Hornberger","year":"2012","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.semradonc.2015.08.002_bib19","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s10549-010-1329-6","article-title":"The effects of oncotype DX recurrence scores on chemotherapy utilization in a multi-institutional breast cancer cohort","volume":"126","author":"Ademuyiwa","year":"2011","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"10.1016\/j.semradonc.2015.08.002_bib20","doi-asserted-by":"crossref","first-page":"R25","DOI":"10.1186\/bcr1412","article-title":"A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients","volume":"8","author":"Habel","year":"2006","journal-title":"Breast Cancer Res"},{"issue":"25","key":"10.1016\/j.semradonc.2015.08.002_bib21","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1200\/JCO.2007.14.4501","article-title":"Prognostic utility of the 21-gene assay in hormone receptor\u2013positive operable breast cancer compared with classical clinicopathologic features","volume":"26","author":"Goldstein","year":"2008","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.semradonc.2015.08.002_bib22","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1200\/JCO.2007.13.6424","article-title":"Estrogen- and progesterone-receptor status in ECOG 2197: Comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory","volume":"26","author":"Badve","year":"2008","journal-title":"JClin Oncol"},{"issue":"13","key":"10.1016\/j.semradonc.2015.08.002_bib23","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1002\/cncr.25206","article-title":"Clinical significance of the 21\u2010gene signature (Oncotype DX) in hormone receptor\u2010positive early stage primary breast cancer in the Japanese population","volume":"116","author":"Toi","year":"2010","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.semradonc.2015.08.002_bib24","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1200\/JCO.2009.23.7610","article-title":"Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: Results from NSABP B-14 and NSABP B-20","volume":"28","author":"Mamounas","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.semradonc.2015.08.002_bib25","first-page":"S6","article-title":"Abstracts of the Society of Surgical Oncology 66th Annual Cancer Symposium. National Harbor, Maryland, USA. March 6-9, 2013","volume":"20","author":"Geary","year":"2013","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"10.1016\/j.semradonc.2015.08.002_bib26","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/jnci\/djt067","article-title":"A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast","volume":"105","author":"Solin","year":"2013","journal-title":"J Natl Cancer Inst"},{"issue":"6871","key":"10.1016\/j.semradonc.2015.08.002_bib27","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/415530a","article-title":"Gene expression profiling predicts clinical outcome of breast cancer","volume":"415","author":"Van\u05f3t Veer","year":"2002","journal-title":"Nature"},{"issue":"19","key":"10.1016\/j.semradonc.2015.08.002_bib28","doi-asserted-by":"crossref","first-page":"10869","DOI":"10.1073\/pnas.191367098","article-title":"Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications","volume":"98","author":"S\u00f8rlie","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"14","key":"10.1016\/j.semradonc.2015.08.002_bib29","doi-asserted-by":"crossref","first-page":"8418","DOI":"10.1073\/pnas.0932692100","article-title":"Repeated observation of breast tumor subtypes in independent gene expression data sets","volume":"100","author":"S\u00f8rlie","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.semradonc.2015.08.002_bib30","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nbt1385","article-title":"Direct multiplexed measurement of gene expression with color-coded probe pairs","volume":"26","author":"Geiss","year":"2008","journal-title":"Nat Biotechnol"},{"issue":"2","key":"10.1016\/j.semradonc.2015.08.002_bib31","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/annonc\/mdt494","article-title":"Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: Using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone","volume":"25","author":"Gnant","year":"2014","journal-title":"Ann Oncol"},{"issue":"22","key":"10.1016\/j.semradonc.2015.08.002_bib32","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1200\/JCO.2012.46.1558","article-title":"Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy","volume":"31","author":"Dowsett","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2015.08.002_bib33","first-page":"32","article-title":"Predicting local recurrence using PAM50 in postmenopausal endocrine responsive breast cancer patients","author":"Fitzal","year":"2014","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.semradonc.2015.08.002_bib34","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1093\/jnci\/djj329","article-title":"Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer","volume":"98","author":"Buyse","year":"2006","journal-title":"J Natl Cancer Inst"},{"issue":"12","key":"10.1016\/j.semradonc.2015.08.002_bib35","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S1470-2045(07)70346-7","article-title":"Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: A prospective community-based feasibility study (RASTER)","volume":"8","author":"Bueno-de-Mesquita","year":"2007","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.semradonc.2015.08.002_bib36","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1158\/1078-0432.CCR-07-4723","article-title":"Analysis of the MammaPrint breast cancer assay in a predominantly postmenopausal cohort","volume":"14","author":"Wittner","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.semradonc.2015.08.002_bib37","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s10549-008-0130-2","article-title":"The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study","volume":"116","author":"Mook","year":"2009","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"10.1016\/j.semradonc.2015.08.002_bib38","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.breast.2012.12.002","article-title":"Additional prognostic value of the 70-gene signature (MammaPrint\u00ae) among breast cancer patients with 4-9 positive lymph nodes","volume":"22","author":"Saghatchian","year":"2013","journal-title":"Breast"},{"issue":"6","key":"10.1016\/j.semradonc.2015.08.002_bib39","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.breast.2012.04.010","article-title":"Additional value of the 70-gene signature and levels of ER and PR for the prediction of outcome in tamoxifen-treated ER-positive breast cancer","volume":"21","author":"Kok","year":"2012","journal-title":"Breast"},{"issue":"3","key":"10.1016\/j.semradonc.2015.08.002_bib40","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s10549-013-2572-4","article-title":"Molecular subtyping of early-stage breast cancer identifies a group of patients who do not benefit from neoadjuvant chemotherapy","volume":"139","author":"Gl\u00fcck","year":"2013","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"10.1016\/j.semradonc.2015.08.002_bib41","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s10549-009-0333-1","article-title":"The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer","volume":"119","author":"Straver","year":"2010","journal-title":"Breast Cancer Res Treat"},{"issue":"12","key":"10.1016\/j.semradonc.2015.08.002_bib42","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1038\/sj.bjc.6605916","article-title":"Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature","volume":"103","author":"Knauer","year":"2010","journal-title":"Br J Cancer"},{"issue":"20","key":"10.1016\/j.semradonc.2015.08.002_bib43","doi-asserted-by":"crossref","first-page":"5272","DOI":"10.1158\/1078-0432.CCR-14-0458","article-title":"Development and validation of a gene profile predicting benefit of postmastectomy radiotherapy in patients with high-risk breast cancer: A study of gene expression in the DBCG82bc cohort","volume":"20","author":"Tramm","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"16","key":"10.1016\/j.semradonc.2015.08.002_bib44","doi-asserted-by":"crossref","first-page":"3667","DOI":"10.1158\/1078-0432.CCR-14-2898","article-title":"Development and validation of a novel radiosensitivity signature in human breast cancer","volume":"21","author":"Speers","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.semradonc.2015.08.002_bib45","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ijrobp.2015.06.021","article-title":"Integration of a radiosensitivity molecular signature into the assessment of local recurrence risk in breast cancer","volume":"93","author":"Torres-Roca","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.semradonc.2015.08.002_bib46","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.ijrobp.2009.06.014","article-title":"A gene expression model of intrinsic tumor radiosensitivity: Prediction of response and prognosis after chemoradiation","volume":"75","author":"Eschrich","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.semradonc.2015.08.002_bib47","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.ijrobp.2009.05.056","article-title":"Systems biology modeling of the radiation sensitivity network: A biomarker discovery platform","volume":"75","author":"Eschrich","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"16","key":"10.1016\/j.semradonc.2015.08.002_bib48","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1056\/NEJMoa022152","article-title":"Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer","volume":"347","author":"Fisher","year":"2002","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.semradonc.2015.08.002_bib49","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1056\/NEJMoa040595","article-title":"Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer","volume":"351","author":"Fyles","year":"2004","journal-title":"N Engl J Med"},{"issue":"9804","key":"10.1016\/j.semradonc.2015.08.002_bib50","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1016\/S0140-6736(11)61629-2","article-title":"Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials","volume":"378","author":"Early Breast Cancer Trialists\u05f3 Collaborative Group","year":"2011","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.semradonc.2015.08.002_bib51","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1200\/JCO.2012.45.2615","article-title":"Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: Long-term follow-up of CALGB 9343","volume":"31","author":"Hughes","year":"2013","journal-title":"J Clin Oncol"}],"container-title":["Seminars in Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053429615000843?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053429615000843?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,19]],"date-time":"2018-09-19T18:25:38Z","timestamp":1537381538000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053429615000843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["S1053429615000843"],"URL":"https:\/\/doi.org\/10.1016\/j.semradonc.2015.08.002","relation":{},"ISSN":["1053-4296"],"issn-type":[{"value":"1053-4296","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular Phenotype, Multigene Assays, and the Locoregional Management of Breast Cancer","name":"articletitle","label":"Article Title"},{"value":"Seminars in Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semradonc.2015.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}